Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $137.4 million.

  • Adma Biologics' Total Non-Current Liabilities fell 1322.49% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year decrease of 1322.49%. This contributed to the annual value of $139.3 million for FY2024, which is 2803.15% down from last year.
  • As of Q3 2025, Adma Biologics' Total Non-Current Liabilities stood at $137.4 million, which was down 1322.49% from $160.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Total Non-Current Liabilities registered a high of $199.8 million during Q3 2022, and its lowest value of $120.4 million during Q2 2021.
  • In the last 5 years, Adma Biologics' Total Non-Current Liabilities had a median value of $180.7 million in 2022 and averaged $166.8 million.
  • In the last 5 years, Adma Biologics' Total Non-Current Liabilities skyrocketed by 5125.53% in 2022 and then tumbled by 3029.82% in 2025.
  • Over the past 5 years, Adma Biologics' Total Non-Current Liabilities (Quarter) stood at $134.7 million in 2021, then soared by 45.63% to $196.1 million in 2022, then dropped by 1.32% to $193.6 million in 2023, then fell by 28.03% to $139.3 million in 2024, then dropped by 1.36% to $137.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $137.4 million for Q3 2025, versus $160.1 million for Q2 2025 and $137.1 million for Q1 2025.